Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Pediatric Rheumatology

Figure 1

From: Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome

Figure 1

Laboratory value responses to tocilizumab in Case 1 (A), Case 2 (B), and Case 3 (C). Platelet counts and Absolute neutrophil counts (ANC) (left column), and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels (right column) from initiation of tocilizumab at Day 0. Arrow indicates dosing of tocilizumab. Note differing x-axis intervals among the three cases.

Back to article page